You’ve outgrown Castor.
Here’s what’s next.

When Castor starts costing you time

The transition from research to regulated trials is a specific inflection point. You need an EDC that’s 21 CFR Part 11 compliant out of the box — not through a workaround or additional configuration. You need an audit trail built in. You need data that comes out submission-ready, not data that requires weeks of cleaning before it’s usable.

If you’re manually bridging the gap between what your current EDC produces and what your regulatory submission requires, your EDC is delaying your study.

OpenClinica vs. Castor

Weeks to go live. Not months.

Switching EDC platforms mid-program is disruptive. Most teams make the move between studies — when they’re standing up their Phase 1 after successful pre-clinical work, or transitioning from a Phase 1 pilot to a larger Phase 2.

The implementation timeline is weeks. The data quality difference shows up immediately — OpenClinica customers report roughly 50% fewer data queries. And because the system is regulatory-ready from day one, your team spends less time on compliance documentation and more time running the study.

I have worked with OpenClinica for more than 15 years and loved how it has developed. The most important pros are the ease of setting up a new study and the management functions. I cannot think of anything [as a con] — I have worked with clinical studies my entire professional life and used any tool on the market, and OpenClinica has resolved all the issues.

— Kristen K., CTO